FR2634397B2 - Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules - Google Patents

Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules

Info

Publication number
FR2634397B2
FR2634397B2 FR888808871A FR8808871A FR2634397B2 FR 2634397 B2 FR2634397 B2 FR 2634397B2 FR 888808871 A FR888808871 A FR 888808871A FR 8808871 A FR8808871 A FR 8808871A FR 2634397 B2 FR2634397 B2 FR 2634397B2
Authority
FR
France
Prior art keywords
nanoparticles
protein
preparation
colloidal systems
dispersible colloidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR888808871A
Other languages
English (en)
Other versions
FR2634397A2 (fr
Inventor
Serge Stainmesse
Hatem Fessi
Jean-Philippe Devissaguet
Francis Puisieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8618446A external-priority patent/FR2608988B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR888808871A priority Critical patent/FR2634397B2/fr
Priority to EP89401856A priority patent/EP0349428B1/fr
Priority to AT89401856T priority patent/ATE84710T1/de
Priority to ES89401856T priority patent/ES2054052T3/es
Priority to DE8989401856T priority patent/DE68904483T2/de
Priority to KR1019890009022A priority patent/KR960014870B1/ko
Priority to US07/374,246 priority patent/US5133908A/en
Priority to JP1169743A priority patent/JPH062224B2/ja
Publication of FR2634397A2 publication Critical patent/FR2634397A2/fr
Publication of FR2634397B2 publication Critical patent/FR2634397B2/fr
Application granted granted Critical
Priority to GR930400469T priority patent/GR3007248T3/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/786—Fluidic host/matrix containing nanomaterials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR888808871A 1986-12-31 1988-06-30 Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules Expired - Lifetime FR2634397B2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR888808871A FR2634397B2 (fr) 1986-12-31 1988-06-30 Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
EP89401856A EP0349428B1 (fr) 1988-06-30 1989-06-28 Procédé de préparation de systèmes colloidaux dispersibles d'une protéine, sous forme de nanoparticules
AT89401856T ATE84710T1 (de) 1988-06-30 1989-06-28 Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
ES89401856T ES2054052T3 (es) 1988-06-30 1989-06-28 Procedimiento de preparacion de sistemas coloidales dispersables de una proteina en forma de nanoparticulas.
DE8989401856T DE68904483T2 (de) 1988-06-30 1989-06-28 Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
KR1019890009022A KR960014870B1 (ko) 1988-06-30 1989-06-29 나노 입자형 단백질의 분산성 교질상 시스템의 제조방법
US07/374,246 US5133908A (en) 1986-12-31 1989-06-30 Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles
JP1169743A JPH062224B2 (ja) 1988-06-30 1989-06-30 極小粒子形の蛋白質の分散性コロイド系の調製方法
GR930400469T GR3007248T3 (fr) 1988-06-30 1993-03-05

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8618446A FR2608988B1 (fr) 1986-12-31 1986-12-31 Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR888808871A FR2634397B2 (fr) 1986-12-31 1988-06-30 Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules

Publications (2)

Publication Number Publication Date
FR2634397A2 FR2634397A2 (fr) 1990-01-26
FR2634397B2 true FR2634397B2 (fr) 1991-04-19

Family

ID=26225686

Family Applications (1)

Application Number Title Priority Date Filing Date
FR888808871A Expired - Lifetime FR2634397B2 (fr) 1986-12-31 1988-06-30 Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules

Country Status (2)

Country Link
US (1) US5133908A (fr)
FR (1) FR2634397B2 (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2125282C (fr) * 1991-12-05 1999-08-31 Jens-Christian Wunderlich Nanosol pharmaceutiquement applicable et methode de preparation
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US20070116761A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
US5364633A (en) * 1994-03-14 1994-11-15 Dow Corning Corporation Silicone vesicles and entrapment
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
WO1997008950A1 (fr) * 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. Systeme permettant de rendre biodisponibles des agents bioalterants sensiblement non solubles
US6391338B1 (en) 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
EP1683517A1 (fr) 1996-08-19 2006-07-26 American Bioscience, Inc. Méthode pour la préparation de particules de proteines pour la libération d' agents pharmacologiques
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
UA52701C2 (uk) 1996-10-11 2003-01-15 Басф Акцієнгезельшафт Твердий засіб захисту рослин та спосіб його одержання, спосіб боротьби з небажаним ростом рослин, спосіб боротьби з шкідливими грибами і тваринами-шкідниками та спосіб регулювання росту рослин
JP3778575B2 (ja) 1997-06-13 2006-05-24 ナノデル テヒノロギーズ ゲーエムベーハー 薬剤標的化システム、その調製方法およびその使用
ES2435944T3 (es) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US20040058006A1 (en) * 1997-10-14 2004-03-25 Alnis Biosciences, Inc. High affinity nanoparticles
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
EP1100475A1 (fr) * 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
EP1127567B1 (fr) * 2000-02-17 2010-09-01 Basf Se Dispersions aqueuses de filtres solaires organiques et insolubles dans l'eau
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
EP1267946A4 (fr) 2000-02-28 2008-07-02 Genesegues Inc Systeme et procede d'encapsulation de nanocapsules
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
AU2002249836B2 (en) * 2000-12-22 2006-12-14 Baxter International Inc. Method for preparing submicron particle suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
ATE329980T1 (de) * 2001-05-02 2006-07-15 Ecosynthetix Inc Verfahren zur herstellung einer wellpappe und die hergestellte wellpappe
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
MXPA04001463A (es) * 2001-08-16 2005-04-29 Trans World New York Llc Sistema de muestreo, recomendacion y compra de medios de usuario personalizado utilizando base de datos de inventario en tiempo real.
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7048771B2 (en) 2001-10-22 2006-05-23 University Of California Dyeing textiles using nanoparticles
ES2260488T3 (es) * 2001-11-07 2006-11-01 Basf Aktiengesellschaft Formulaciones solidas y formulaciones en dispersion para la proteccion de cultivos y su uso en agricultura.
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
EP2283864A1 (fr) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Composition liquide contenant des nanoparticules stabilisées d'une substance active
WO2004053056A2 (fr) * 2002-09-24 2004-06-24 University Of Kentucky Research Foundation Systeme d'administration de vaccin a base de nanoparticules contenant un adjuvant
EP1585548B1 (fr) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions et methodes d'administration d'agents pharmacologiques
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2534924A1 (fr) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Nouvelles compositions de metaxalone
DE10351004A1 (de) * 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
WO2005051511A1 (fr) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation Methode de production de particules fines d'un compose organique
EP1711163A2 (fr) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions preparees avec des agents autostabilisants
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
US7951396B2 (en) * 2005-03-28 2011-05-31 Regeron, Inc. Preparation of nanoliposome-encapsulating proteins and protein-encapsulated nanoliposome
CA2626016A1 (fr) * 2005-10-21 2007-06-21 Panacea Biotec Limited Nouvelles compositions ameliorees pour la therapie du cancer
WO2008051245A2 (fr) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticules destinees a etre utilisees dans des compositions immunogenes
US20070166386A1 (en) * 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2162120B1 (fr) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable
WO2008149230A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
EP2240162A4 (fr) 2007-12-06 2013-10-09 Bend Res Inc Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
EP2231169B1 (fr) 2007-12-06 2016-05-04 Bend Research, Inc. Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
ES2498091T3 (es) * 2008-04-28 2014-09-24 Novartis Ag Procedimiento para producir nanopartículas
CA2730760A1 (fr) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Procede pour preparer des microparticules contenant des peptides bioactifs
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
WO2011093416A1 (fr) 2010-01-29 2011-08-04 富士フイルム株式会社 Composition pharmaceutique et préparation pour administration par voie orale
BRPI1004808B1 (pt) 2010-10-27 2020-09-29 Embrapa - Empresa Brasileira De Pesquisa Agropecuária Composições baseadas em nanopartículas de própolis, processos de obtenção e uso
WO2012059936A1 (fr) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Compositions pharmaceutiques destinées à l'administration de médicaments colloïdaux
WO2015071841A1 (fr) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci
US10624499B2 (en) * 2014-07-30 2020-04-21 North American Robotics Corporation Systems and methods for pressure control in automated blending devices
EP3188716B1 (fr) 2014-09-03 2022-10-26 GeneSegues, Inc. Nanoparticules thérapeutiques et compositions, procédés et systèmes associés
US10301506B2 (en) * 2016-06-06 2019-05-28 Cymer-Dayton, Llc Full scale process for preparing polymer powders
WO2018071864A1 (fr) 2016-10-13 2018-04-19 Thomas Jefferson University Compositions d'administration, et leurs procédés de préparation et d'utilisation
CN108113008B (zh) * 2016-11-28 2021-12-17 丰益(上海)生物技术研发中心有限公司 一种减少脂肪消化的乳液及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH201942A (de) * 1935-07-08 1938-12-31 A Dr Krause Georg Verfahren zur Herstellung von Solen bezw. Suspensionen organischer Substanzen.
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules

Also Published As

Publication number Publication date
US5133908A (en) 1992-07-28
FR2634397A2 (fr) 1990-01-26

Similar Documents

Publication Publication Date Title
MA22626A1 (fr) Procede de preparation d'acides imidazolyl-alcenoiques .
MA21682A1 (fr) Procede de preparation d'agents therapeutiques derives de la quainclidine.
MA22481A1 (fr) Procede de preparation d'acides imidazolyl - alcenoiques .
FR2725208B1 (fr) Procede de preparation de composes de silicium biologiquement actifs sous forme concentree
MA22668A1 (fr) Procede de preparation d'oxamides .
FR2650182B1 (fr) Procede de preparation d'une composition pharmaceutique sous forme de microparticules
MA21323A1 (fr) Dihydrate d'azithromycine et son procede de preparation.
FI891338L (fi) Parannus menetelmään 2',3'-dideoksi-2',3'-didehydronukleosidien valmistamiseksi
FR2530399B1 (fr) Vehicule articule, notamment sous forme d'une machine agricole
FR2628324B1 (fr) Compositions pharmaceutiques antivirales et immunostimulantes et procede pour les preparer
FR2627493B1 (fr) Procede de preparation de derives d'isoquinoleine
FR2688506B1 (fr) Procede de preparation de sels de l'acide clavulanique.
EP0328924A3 (fr) Composés de thiénotriazolodiazépine et ses applications pharmaceutiques
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
HU913119D0 (en) 4- or 5-substituted piridine-2-carbonic acids and process for their- and for medical preparations'production that contain the compound
FR2666334B1 (fr) Procede continu de preparation d'acrylamides et de methacrylamides n-substitues.
FR2677012B1 (fr) Dioxyde de titane sous forme de plaquettes et son procede de preparation.
FR2630735B1 (fr) Procede de preparations d'halogenophenols
EP0297296A3 (en) Process for the preparation of 2,2'-oxybisûn,n-dimethyl-ethylamine¨
FR2720944B1 (fr) Composition thérapeutique ou diététique sous forme de gel médicamenteux pour l'administration à des animaux de compagnie.
FR2647446B1 (fr) Procede pour la preparation selective de 1,4-diamino-2-nitrobenzenes substitues en n4
RO89437A (fr) Procede pour la preparation d'une forme galenique de sulpyride
FR2677354B1 (fr) Procede pour la preparation d'esters d'acides racemisables.
EP0499232A3 (en) 4-oxo-azetidine-2-sulfonic acids and their salts, processes for the preparation thereof and their use
FR2686876B1 (fr) Procede de preparation d'acides arylacetiques et de leurs sels de metaux alcalins.